Centauri Therapeutics’ strategy is to redirect naturally occurring antibodies to target disease. Our unique Chemistry Platform provides a flexible scaffold to enable the synthesis of specific Alphamers. These are bifunctional molecules which present a selective cell binding moiety as well as an epitope that recruits pre-existing antibodies, resulting in cell killing. We believe our technology is widely applicable in the treatment of life threatening infectious diseases.
Companies with an interest in accessing Centauri’s Alphamer technology or with an interest in one of our current projects, are warmly encouraged to contact us to discuss partnering opportunities.